Penumbra, Inc. (PEN) AI Stock Analysis

Penumbra, Inc. is a global leader in the design, development, manufacturing, and distribution of innovative medical devices for neurovascular and vascular disorders. The company's core portfolio features aspiration-based mechanical thrombectomy systems, including brands like Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE. For neurovascular applications, it provides embolization coiling systems such as Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil, alongside access systems including Neuron, Neuron MAX, Select, and BENCHMARK. It also manufactures Artemis Neuro Evacuation Device tools for neurosurgery, Indigo System thrombectomy platforms for vascular treatments, and Ruby Coil systems for peripheral embolization.

Penumbra increased revenue from $747.6M in FY2021 to $1.40B in FY2025, generating a 5-year revenue CAGR of 20.2% through FY2025. Annual revenue growth improved to 17.5% in FY2025 from 12.9% in FY2024. Over this period, gross margin rose from 63.6% in FY2021 to 67.1% in FY2025, while operating margin expanded from -1.0% to 13.5%. Net income rebounded from -$2.0M in FY2022 to $177.7M in FY2025, yielding an EPS of $3.84. For the trailing twelve months ended June 30, 2026, revenue was $1.50B with an operating margin of 10.5%. In the quarter ended June 30, 2026, quarterly revenue grew 14.9% year-over-year, while quarterly earnings declined 23.5%.

As of June 30, 2026, Penumbra held $658.8M in cash and short-term investments alongside total debt of $212.7M, resulting in net cash of $446.1M. Liquidity remains sound with a current ratio of 5.75 and a debt-to-equity ratio of 0.14 relative to $1.53B in shareholders' equity. In FY2025, the business generated $238.7M in operating cash flow and $174.9M in free cash flow. Cash allocation in FY2025 included $63.7M dedicated to capital expenditures, while share issuance contributed $31.8M, with share count increasing 5.7% over 5 years.

At $320.86 per share, Penumbra carries a market capitalization of $12.64B and an enterprise value of $12.14B. The stock trades at a trailing P/E of 78.8x and a forward P/E of 55.6x, compared to medians of 24.6x and 17.3x for its US-listed Healthcare peers. Its price-to-sales multiple is 8.4x versus the peer median of 4.1x, and its EV/EBITDA is 54.6x versus 12.0x for peers. Over the past year, the stock returned 26.4%, outperforming the S&P 500 return of 16.8%, but its 5-year return of 19.8% lagged the S&P 500 gain of 83.0%.

Consensus ratings on Penumbra include 2 Strong Buy, 1 Buy, 14 Hold, and 0 Sell ratings. The average price target of $362.54 indicates an upside of 13.0% from the recent close of $320.86. For the fiscal year ending December 31, 2026, analysts expect EPS of $4.81 on revenue of $1.59B, reflecting 25.4% projected EPS growth. For the following fiscal year, 13 analysts project EPS of $6.13 on revenue of $1.80B. The company beat earnings expectations in 2 of the last 4 quarters and is set to report results on November 4, 2026.

This page is an AI-written research summary of Penumbra, Inc. (PEN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PEN income statement, PEN balance sheet, PEN key metrics, PEN analyst forecast, PEN chart. See the PEN stock overview for the latest quote and news.